HIV & AIDS Health Center

Font Size
A
A
A

New HIV Drug Intelence Approved

FDA Approves Intelence for Use in Adults Not Helped by Other Antiretroviral Drugs
By Miranda Hitti
WebMD Health News
Reviewed by Louise Chang, MD

Jan. 25, 2008 -- The FDA has approved a new HIV drug called Intelence.

Intelence is approved for use with other HIV drugs in adults who haven't been helped by other antiretroviral drugs.

Intelence belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It helps to block an enzyme that HIV needs to multiply.

Intelence was developed based on its ability to counter HIV strains that resist NNRTI  treatment.

"This is another significant new product for many HIV-infected patients who are NNRTI-resistant and whose infections are not responding to currently available medications," Debra Birnkrant, MD, director of the FDA's antiviral products division, says in a news release.

Intelence Approved

The FDA fast-tracked its review of Intelence and approved the drug based mainly on data from two studies.

Together, the studies included 599 adult HIV patients. Half of the patients got Intelence in addition to their other HIV drugs. The other half of the group got a placebo pill along with their other HIV drugs.

After six months of treatment, more patients in the Intelence group had a drop in their blood level of HIV than patients in the placebo group.

Side Effects

Rash and nausea were the most commonly reported side effects in the two Intelence studies reviewed by the FDA.

The FDA also notes that while Intelence was being developed, there were rare cases of skin reactions, such as Stevens-Johnson syndrome (a severe skin disorder) and erythema multiforme (which is usually less severe than Stevens-Johnson syndrome).

Patients taking Intelence may develop infections, including opportunistic infections or other conditions that may develop in people living with HIV.

The long-term effects of Intelence aren't known, and the drug's safety and effectiveness haven't been studied in children younger than 16 or in pregnant women.

The FDA has this advice for people taking Intelence:

  • Contact your doctor if you develop a rash while taking Intelence.
  • Tell your doctor and pharmacist about all the medications you take, in order to avoid drug interactions.
  • Women who become pregnant while taking Intelence or other HIV drugs should consult a doctor.

Intelence is a product of Tibotec Therapeutics, a division of Ortho Biotech Products of Bridgewater, N.J.

webMD Video

Show or hide information about video: AIDS Vaccine Trial   AIDS Vaccine Trial

needle and vaccine

Finding a vaccine to prevent aids is a major challenge. HIV is one of the most complicated viruses there is. Here’s one novel way to attack the virus and prevent infection.

Watch Video: AIDS Vaccine Trial (opens in a new window)

Show or hide information about video: HIV Vaccine   HIV Vaccine

Show or hide information about video: Fast HIV Screening   Fast HIV Screening

Show or hide information about video: Microbicides for HIV Protection?   Microbicides for HIV Protection?

Show or hide information about video: HIV Test for Early Detection   HIV Test for Early Detection

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.